A Phase Ib/II, Open Label, Multicenter Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies
Latest Information Update: 07 Jan 2022
At a glance
- Drugs Lacnotuzumab (Primary) ; Spartalizumab (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Endometrial cancer; Malignant melanoma; Pancreatic cancer; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis; Novartis Pharma; Novartis Pharmaceuticals
- 12 Jul 2021 Number of treatment arms have been increased from 4 to 11 by the addition of 4 new phase-2 arms and 2 new phase-1b arms. the previously existing arms have also been labelled as phase-1 b arms. Additionally, 9 new primary end-points have been added.
- 21 May 2021 Results presented at the 112th Annual Meeting of the American Association for Cancer Research
- 09 Jul 2020 Status changed from active, no longer recruiting to completed.